The Neuromuscular Effect of Rocuronium in Patient

Go Eun Bae

Status: Unknown

Conditions: Anesthesia

Treatments: Device: Inbody; Drug: Rocuronium

Study type: Interventional

Funder types: Other

Identifiers

NCT02657187

Inbody2

Details and patient eligibility

About

Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction. The purpose of this study is to find 50% effective dose and 95% effective dose of rocuronium according to muscle mass.

Full description

Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction. Until now, dose of rocuronium has been judged by patient's weight and height. When the rocuronium was developed, 50% effective dose and 95% effective dose of rocuronium was calculated by patient corrected body weight which used weight and height. However, height and weight do not represent exact muscle mass. The purpose of this study is to find 50% effective dose and 95% effective dose of rocuronium according to muscle mass. Measurement of muscle mass will be obtained using bioelectrical impedence analysis.

Enrollment: 80 estimated patients

Sex: All

Ages: 19 to 64 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• All patient who undergo general anesthesia

Exclusion criteria

• Liver and kidney disease
• Any types of muscle disorder.
• Metal materials or pacemaker in body

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

80 participants in 4 patient groups

rocuronium 1

Experimental group

Description:

Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.24mg per muscle mass(kg).

Treatment:

Drug: Rocuronium

Device: Inbody

rocuronium 2

Experimental group

Description:

Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.32mg per muscle mass(kg).

Treatment:

Drug: Rocuronium

Device: Inbody

rocuronium 3

Experimental group

Description:

Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.40mg per muscle mass(kg).

Treatment:

Drug: Rocuronium

Device: Inbody

rocuronium 4

Experimental group

Description:

Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.48mg per muscle mass(kg).

Treatment:

Drug: Rocuronium

Device: Inbody